Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Unternehmen & Branche
| Name | Celldex Therapeutics, Inc. |
|---|---|
| Ticker | CLDX |
| CIK | 0000744218 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2835 · In Vitro & In Vivo Diagnostic Substances |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,23 Mrd. USD |
| Beta | 1,20 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,545,000 | -258,757,000 | -3.90 | 582,983,000 | 527,165,000 |
| 2025-09-30 | 10-Q | 1,424,000 | -67,044,000 | -1.01 | 648,439,000 | 598,363,000 |
| 2025-06-30 | 10-Q | 730,000 | -56,600,000 | -0.85 | 692,407,000 | 655,406,000 |
| 2025-03-31 | 10-Q | 695,000 | -53,796,000 | -0.81 | 739,471,000 | 702,981,000 |
| 2024-12-31 | 10-K | 7,020,000 | -157,863,000 | -2.45 | 792,340,000 | 747,005,000 |
| 2024-09-30 | 10-Q | 3,191,000 | -42,121,000 | -0.64 | 823,179,000 | 785,905,000 |
| 2024-06-30 | 10-Q | 2,498,000 | -35,842,000 | -0.54 | 845,586,000 | 813,659,000 |
| 2024-03-31 | 10-Q | 156,000 | -32,808,000 | -0.56 | 868,847,000 | 838,613,000 |
| 2023-12-31 | 10-K | 6,883,000 | -141,429,000 | -2.92 | 465,627,000 | 429,171,000 |
| 2023-09-30 | 10-Q | 1,517,000 | -0.81 | 280,256,000 | 246,718,000 | |
| 2023-06-30 | 10-Q | 268,000 | -0.65 | 299,311,000 | 277,537,000 | |
| 2023-03-31 | 10-Q | 967,000 | -0.62 | 324,519,000 | 302,740,000 | |
| 2022-12-31 | 10-K | 2,357,000 | -2.40 | 352,735,000 | 326,204,000 | |
| 2022-09-30 | 10-Q | 407,000 | -0.57 | 369,226,000 | 345,416,000 | |
| 2022-06-30 | 10-Q | 163,000 | -0.77 | 402,961,000 | 365,093,000 | |
| 2022-03-31 | 10-Q | 174,000 | -0.49 | 424,041,000 | 398,101,000 | |
| 2021-12-31 | 10-K | 4,651,000 | -1.64 | 444,654,000 | 419,476,000 | |
| 2021-09-30 | 10-Q | 153,000 | -0.45 | 460,201,000 | 436,712,000 | |
| 2021-06-30 | 10-Q | 3,480,000 | -0.34 | 204,551,000 | 182,282,000 | |
| 2021-03-31 | 10-Q | 685,000 | -0.42 | 219,065,000 | 194,166,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-04 | Jimenez Freddy A. | Officer, SVP & GENERAL COUNSEL | Open Market Sale | -4,166 | 29.10 | -121,209.77 | -36,6% | |
| 2025-11-13 | Wright Richard M. | Open Market Sale | -49,298 | 24.00 | -1,183,176.65 | -357,6% | ||
| 2025-08-13 | Jimenez Freddy A. | Officer, SVP & GENERAL COUNSEL | Open Market Sale | -341 | 23.95 | -8,167.46 | -2,5% | |
| 2025-08-13 | Jimenez Freddy A. | Officer, SVP & GENERAL COUNSEL | Open Market Sale | -430 | 25.42 | -10,928.45 | -3,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.